Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atipamezole + caffeine
- Development stage
- Unknown
- Lead developer
- University of Chicago
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination is used to rapidly reverse sedation caused by dexmedetomidine. Atipamezole acts as an α2-adrenergic receptor antagonist, competing with dexmedetomidine for receptor binding sites, thereby reversing its sedative effects. Caffeine enhances this reversal by acting as a stimulant, further accelerating emergence from sedation.
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADRA2A (α2A)ADOR (Adenosine receptors)
Beyond the preview
Go deeper on atipamezole + caffeine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atipamezole + caffeine.